Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) have earned a consensus recommendation of “Buy” from the eleven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $53.33.
SUPN has been the subject of a number of analyst reports. Jefferies Financial Group set a $46.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. TheStreet lowered shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 29th. Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. ValuEngine raised shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th.
In other news, CEO Jack A. Khattar purchased 7,200 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $26.39 per share, with a total value of $190,008.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.57% of the stock is owned by insiders.
SUPN traded up $0.64 during trading on Monday, reaching $25.86. 667,312 shares of the company’s stock were exchanged, compared to its average volume of 571,118. The company’s fifty day moving average price is $27.34 and its 200-day moving average price is $31.73. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.53 and a current ratio of 2.72. Supernus Pharmaceuticals has a fifty-two week low of $25.15 and a fifty-two week high of $49.47. The firm has a market capitalization of $1.35 billion, a PE ratio of 13.20, a P/E/G ratio of 0.90 and a beta of 1.61.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The firm had revenue of $104.70 million during the quarter, compared to analyst estimates of $109.67 million. During the same quarter in the previous year, the business earned $0.57 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Research analysts forecast that Supernus Pharmaceuticals will post 2.16 earnings per share for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Further Reading: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.